Xspray Pharma publishes Interim Report Q2, January – June 2019
August 29, 2019 ”We have previously shown that it is possible to manufacture small pilot quantities of amorphous material for clinical studies but now we have shown that the process works at commercial scale. We have ”cracked the code”, so to speak, and have taken a great step toward a finished product.” Per Andersson, CEO Xspray Pharma AB (publ) Significant events during the second quarter 2019 · In June, Xspray announced the successful start of HyNap-Dasa production in the Company’s unique full-scale manufacturing facility in Italy · In June, Xspray was granted